Concord Drugs Balance Sheet Annual

BSE: 538965 | NSE: - | ISIN: INE858L01010 | Sector: Biotechnology & Drugs

79.70 -1.12 (-1.39%)Updated : 07 Sep 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Liabilities Shareholders' Equity	74.89	65.14	58.81	58.23
Other Liabilities Total	2.88	2.90	2.53	2.46
Long Term Debt	1.81	1.32	0.65	1.91
Common Stock Total	13.18	10.00	10.00	9.32
Other Current Assets Total	2.63	1.54	1.64	7.34
Total Assets	74.89	65.14	58.81	58.23
Current Portof LT Debt/ Capital Leases	12.70	17.92	16.87	15.05
Cash	0.75	0.23	0.18	0.10
Total Equity	48.51	34.11	33.82	31.70
Long Term Investments	1.42	1.44	1.48	1.53
Retained Earnings( Accumulated Deficit)	35.34	24.11	23.82	22.39
Total Common Shares Outstanding	1.00	1.00	1.00	0.93
Tangible Book Valueper Share Common Eq	48.51	34.11	33.82	34.03
Total Liabilities	26.37	31.03	24.99	26.53
Total Debt	14.51	19.24	17.52	16.96
Short Term Investments	0.04	0.12	0.05	0.14
Cashand Short Term Investments	0.79	0.35	0.22	0.24
Total Receivables Net	24.38	13.60	19.83	15.81
Deferred Income Tax	0.62	0.63	0.47	0.54
Accounts Receivable- Trade Net	24.38	13.60	19.83	15.81
Property/ Plant/ Equipment Total- Net	13.37	13.57	12.67	13.20
Total Current Liabilities	21.07	26.18	21.34	21.61
Total Inventory	25.52	25.27	22.92	20.06
Accounts Payable	7.07	7.62	3.44	5.27
Other Currentliabilities Total	1.29	0.64	1.03	1.29
Total Long Term Debt	1.81	1.32	0.65	1.91
Other Long Term Assets Total	6.71	0.00	-	0.00
Note Receivable- Long Term	0.08	9.37	0.04	0.04
period Length	0.00	0.00	0.00	0.00
Total Current Assets	53.31	40.76	44.61	43.46
Notes Payable/ Short Term Debt	-	0.00	0.00	0.00
Other Equity Total	-	-	-	0.00